Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study.

Samuel Rosner1, Alexander I Spira2,3,4

  • 1Medical Oncology, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.

Summary

New therapies targeting MET exon 14 skipping non-small cell lung cancer (NSCLC) are approved. Further research on tepotinib will identify patient subgroups benefiting most from this emerging treatment.